Physician profile
Grisel Diaz
NPI 1982928115
$5,283.36
in general payments reported to CMS, 2019-2025
34 companies · $1,496 in 2025
The $1,496 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $421 · 2022: $733 · 2023: $1,186 · 2024: $1,447 · 2025: $1,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,129.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $784.63 | 2022-2025 | Enhertu, Injectafer |
| Genzyme Corporation | $558.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $360.83 | 2022-2025 | |
| Incyte Corporation | $344.05 | 2022-2025 | Jakafi |
| Sobi, INC | $319.28 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $308.69 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pharmaessentia USA Corporation | $275.76 | 2024-2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $259.86 | 2023-2025 | Monoferric |
| Astrazeneca Pharmaceuticals Lp | $226.72 | 2023-2025 | Enhertu |
| Agios Pharmaceuticals, INC. | $222.63 | 2022-2025 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $219.15 | 2022 | |
| Pfizer INC. | $152.27 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $138.53 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $114.99 | 2021 | |
| Amgen INC. | $113.29 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $102.29 | 2022-2023 | Vonvendi |
| Janssen Pharmaceuticals, INC | $74.12 | 2023-2024 | Xarelto |
| Lilly USA, LLC | $72.26 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Recordati_rare_diseases_inc. | $69.04 | 2024 | Sylvant |
| Apellis Pharmaceuticals, INC. | $63.70 | 2022-2025 | Empaveli |
| Blueprint Medicines Corporation | $57.24 | 2025 | Ayvakit |
| Springworks Therapeutics, INC. | $55.09 | 2025 | Ogsiveo |
| Alnylam Pharmaceuticals INC. | $50.75 | 2022-2023 | Givlaari |
| Dova Pharmaceuticals | $46.64 | 2021 | |
| Eisai INC. | $41.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $38.73 | 2024 | Onivyde, Somatuline Depot |
| Global Blood Therapeutics, INC. | $36.78 | 2022 | |
| Sanofi-Aventis U.S. LLC | $34.34 | 2025 | |
| Taiho Oncology, INC. | $28.57 | 2025 | |
| Jazz Pharmaceuticals INC. | $24.28 | 2025 | |
| Genmab U.S., INC. | $23.81 | 2025 | Epkinly |
| Kedrion Biopharma, INC. | $22.62 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Adaptive Biotechnologies Corporation | $22.23 | 2023 | Clonoseq |
| Csl Behring | $20.21 | 2023 | Idelvion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grisel Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.